Evidence map›Paper›PMID 40287726›Full record

ArticleCell & bioscience2025

The chromatin reader Dido3 is a regulator of the gene network that controls B cell differentiation.

Fernando Gutiérrez Del Burgo, María Ángeles García-López, Tirso Pons, Enrique Vázquez de Luis, Carlos Martínez-A, Ricardo Villares

Abstract read
In one paragraph

Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fernando Gutiérrez Del BurgoCentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain.
María Ángeles García-LópezCentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain.
Tirso PonsCentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain.
Enrique Vázquez de LuisCentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain.
Carlos Martínez-ACentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain.
Ricardo VillaresCentro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, E-28049, Madrid, Spain. rvillares@cnb.csic.es.ORCID http://orcid.org/0000-0001-7562-6700

Funding

Comunidad de Madrid S2022/BMD-7321/MITIC-CMFundación Ramón Areces CPRI2016Ministerio de Ciencia e Innovación PID2019-110574RB-I00Ministerio de Ciencia e Innovación SAF2016-75456-RMinisterio de Ciencia e Innovación SEV-2017-0712
6 · The paper itself

Abstract

The development of hematopoietic cell lineages is a highly complex process governed by a delicate interplay of various transcription factors. The expression of these factors is influenced, in part, by epigenetic signatures that define each stage of cell differentiation. In particular, the formation of B lymphocytes depends on the sequential silencing of stemness genes and the balanced expression of interdependent transcription factors, along with DNA rearrangement. We have investigated the impact of Dido3 deficiency, a protein involved in chromatin status readout, on B cell differentiation within the hematopoietic compartment of mice. Our findings revealed significant impairments in the successive stages of B cell development. The absence of Dido3 resulted in remarkable alterations in the expression of essential transcription factors and differentiation markers, which are crucial for orchestrating the differentiation process. Additionally, the somatic recombination process, responsible for generation of antigen receptor diversity, was also adversely affected. These observations highlight the vital role of epigenetic regulation, particularly the involvement of Dido3, in ensuring proper B cell differentiation. This study reveals new mechanisms underlying disruptive alterations, deepening our understanding of hematopoiesis and may potentially lead to insights that aid in the development of therapeutic interventions for disorders involving aberrant B cell development.

Identifiers

PMID40287726
PMCPMC12034202

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.